A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
暂无分享,去创建一个
C. Perou | M. Dowsett | J. Parker | J. Albanell | A. Lluch | A. Turnbull | A. Prat | B. Adamo | E. Alba | N. Ribelles | J. Dixon | A. Dunbier | E. Carrasco | L. Calvo | R. Caballero | Miguel Martín | M. Muñoz | P. Sánchez‐Rovira | J. Chacón | Á. Arcusa | J. R. De la Haba-Rodríguez | L. Paré | A. Plazaola | B. Jímenez | Abdul Aziz Bin Aiderus
[1] Ian Krop,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Bast,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Charles M. Perou,et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy , 2015, BMC Medicine.
[4] R. Price,et al. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data , 2015, BMC Medicine.
[5] S. Ferree,et al. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay , 2015, Clinical Cancer Research.
[6] M. Dowsett,et al. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Collins,et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement , 2015, BMC medicine.
[8] Christos Sotiriou,et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E Mardis,et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer , 2014, British Journal of Cancer.
[10] C. Perou,et al. Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer , 2014, Journal of the National Cancer Institute.
[11] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[12] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] C. Perou,et al. Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice , 2013, Clinical Cancer Research.
[14] Donald A. Berry,et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer , 2013, Breast Cancer Research and Treatment.
[15] L. Pusztai,et al. Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer , 2013, Clinical Cancer Research.
[16] C. Perou,et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[18] J. Albanell,et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[20] C. Fan,et al. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.
[21] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Fan,et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[24] Charles M. Perou,et al. Practical implications of gene-expression-based assays for breast oncologists , 2012, Nature Reviews Clinical Oncology.
[25] C. Perou,et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole , 2011, Steroids.
[26] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Esserman,et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.
[28] Charles M. Perou,et al. Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.
[29] Yufeng Liu,et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures , 2011, BMC Medical Genomics.
[30] Jie Chen,et al. Gene expression in cardiac tissues from infants with idiopathic conotruncal defects , 2011, BMC Medical Genomics.
[31] Peter Regitnig,et al. Genomic index of sensitivity to endocrine therapy for breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Mark T. W. Ebbert,et al. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.
[33] C. Perou,et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Jennifer L. Osborn,et al. Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.
[36] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] C. Sotiriou,et al. Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer , 2007, Clinical Cancer Research.
[38] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[39] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[41] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[42] A. Hutcheon,et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.
[43] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[44] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[45] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[46] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.